Will I Lose Weight on Wegovy — and How Much Can You Realistically Expect?

In clinical trials, Wegovy produced an average weight loss of around 15% of body weight over 68 weeks at the 2.4mg maintenance dose, and a higher 7.2mg dose approved by the MHRA in 2026 has shown around 20.7% average loss in trials.
Results vary significantly between individuals: some people lose considerably more, some less, and a prescriber reviews your response before every repeat prescription.
Wegovy works by activating GLP-1 receptors that regulate appetite and slow gastric emptying, so the treatment supports a calorie deficit rather than replacing it, diet and activity still matter.
If you lose less than 5% of your body weight after six months on the maintenance dose, NICE guidance recommends reconsidering whether to continue.

Most people who take Wegovy do lose a meaningful amount of weight. In the pivotal STEP 1 trial, adults using semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight over 68 weeks — roughly 15 kg for someone starting at 100 kg. That figure comes from a large, rigorous trial, not a marketing sheet. How much you personally lose depends on several factors that are worth understanding before you start, because Wegovy is a prescription-only medicine and a clinician needs to assess whether it is appropriate for you and at what dose. This page walks through the decision you are actually making, not just whether Wegovy works in general, but what shapes results for individuals and what to expect along the way. Learn more about semaglutide and the biology behind how it reduces appetite.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What actually determines how much weight you lose on semaglutide

The trial results are real, so why do outcomes differ so much person to person?

The STEP 1 trial results are striking, and they are genuine. Published in the New England Journal of Medicine, the study found roughly 15% average weight loss over 68 weeks among adults who took semaglutide 2.4mg alongside a reduced-calorie diet and increased activity. About one in three participants lost 20% or more. Those are population averages, though, and averages conceal a wide spread.

The spread exists because weight is shaped by biology. Starting body weight, metabolic rate, how your gut absorbs the medicine, how far you have already titrated your dose, sleep, stress, any underlying conditions, all of these influence your individual trajectory. There is a persistent misconception that GLP-1 medicines simply melt fat regardless of what else you do. They do not. Wegovy reduces appetite and slows the rate at which your stomach empties, which makes eating less far more manageable. The calorie deficit still has to happen; the medicine makes it easier to sustain.

One thing that does not vary: the evidence is built on lifestyle change alongside the injection, not instead of it. If you want to understand how to get the most from Wegovy in practice, what you eat and how active you are genuinely moves the needle on your personal outcome.

When you should start to see weight coming off

The titration schedule is gradual by design. Wegovy starts at 0.25mg for four weeks, then increases in stages, typically reaching 2.4mg at around month five. The early doses are primarily about tolerability (letting your system adjust) so the period when will i lose weight on semaglutide becomes a real question for many people is usually after the first dose increase, around weeks four to eight.

Most people notice appetite changes before the scales shift. Fullness arrives earlier at meals, the urge to snack fades, and portion sizes naturally contract. Weight loss that shows up on the scales tends to lag slightly behind those subjective changes. A closer look at the early timeline can help set realistic expectations for the first month or two, which is the phase when people most often worry that nothing is happening.

Progress also accelerates as the dose increases toward maintenance. If your prescriber has approved a step up, the effect on appetite typically deepens within a week or two of the new dose. Tracking your weight weekly rather than daily tends to reduce unnecessary anxiety, because day-to-day fluctuations in water retention can obscure the underlying trend. Some people also notice unexpected changes in mood or desire at this stage, and if you are curious about whether Wegovy affects libido and what the evidence says, it is a more common question than many people expect.

The 5% threshold, and what happens if you reach it slowly or not at all

NICE guidance on semaglutide (Wegovy) sets a clear checkpoint: if someone loses less than 5% of their body weight after six months on their maintenance dose, the clinical recommendation is to reconsider whether continuing treatment is appropriate. That is not a punishment, it is a recognition that the medicine does not work the same way for everyone, and that continuing indefinitely without meaningful benefit is not in the patient's interest.

That threshold matters when you are deciding whether to start, because it frames Wegovy as a clinically monitored treatment rather than a supplement you take indefinitely regardless of effect. Every repeat prescription at nume is reviewed by a GPhC-registered prescriber before it is approved. Your progress is part of that review. The question of whether semaglutide will specifically help you is one your prescriber explores at consultation, looking at your health history, your current weight, and any conditions that might affect your response.

For context on what legitimate, regulated private treatment involves and what to expect in terms of cost, the guide to accessing Wegovy safely in the UK covers the supply chain and what a genuine pharmacy process looks like. You can also read about how the nume team is structured and the clinical oversight behind every prescription. When you are ready to speak to a prescriber about your own circumstances, starting with a free consultation is the straightforward next step.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions